Progress towards molecular-based management of childhood Langerhans cell histiocytosis.


Journal

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
ISSN: 1769-664X
Titre abrégé: Arch Pediatr
Pays: France
ID NLM: 9421356

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 30 10 2018
revised: 13 05 2019
accepted: 30 05 2019
pubmed: 10 7 2019
medline: 21 1 2020
entrez: 9 7 2019
Statut: ppublish

Résumé

Langerhans cell histiocytosis (LCH) is characterized by inflammatory lesions containing abundant CD1a+ CD207+ histiocytes that lead to the destruction of affected tissues. This disease has a remarkable pleiotropic clinical presentation and most commonly affects young children. Although the current mortality rate is very low for childhood LCH patients (<2%), reactivation frequently occurs after a long period of disease control and the rates of permanent complications and sequelae remain high. Advances in genomic sequencing technologies in this past decade have highlighted somatic molecular alterations responsible for the disease in around 80% of childhood LCH cases. More than half of these cases harbored the BRAF

Identifiants

pubmed: 31281037
pii: S0929-693X(19)30103-4
doi: 10.1016/j.arcped.2019.05.015
pii:
doi:

Substances chimiques

Genetic Markers 0
Imidazoles 0
Oximes 0
Protein Kinase Inhibitors 0
Vemurafenib 207SMY3FQT
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
MAP Kinase Kinase 1 EC 2.7.12.2
MAP2K1 protein, human EC 2.7.12.2
dabrafenib QGP4HA4G1B

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

301-307

Informations de copyright

Copyright © 2019 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

S Héritier (S)

Faculté de médecine, Sorbonne Université, 75013 Paris, France; Service d'hématologie oncologie pédiatrique, centre de référence des histiocytoses, hôpital Armand-Trousseau, Assistance publique-Hôpitaux de Paris, 6, avenue du Dr Netter, 75012 Paris, France; EA4340, UVSQ, université Paris-Saclay, 92100 Boulogne-Billancourt, France. Electronic address: sebastien.heritier@aphp.fr.

J-F Emile (JF)

EA4340, UVSQ, université Paris-Saclay, 92100 Boulogne-Billancourt, France; Département de pathologie, hôpital Ambroise-Paré, Assistance publique-Hôpitaux de Paris, 92104 Boulogne-Billancourt, France.

Z Hélias-Rodzewicz (Z)

EA4340, UVSQ, université Paris-Saclay, 92100 Boulogne-Billancourt, France; Département de pathologie, hôpital Ambroise-Paré, Assistance publique-Hôpitaux de Paris, 92104 Boulogne-Billancourt, France.

J Donadieu (J)

Service d'hématologie oncologie pédiatrique, centre de référence des histiocytoses, hôpital Armand-Trousseau, Assistance publique-Hôpitaux de Paris, 6, avenue du Dr Netter, 75012 Paris, France; EA4340, UVSQ, université Paris-Saclay, 92100 Boulogne-Billancourt, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH